Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
29 Novembro 2023 - 10:00AM
Business Wire
Expands intellectual property portfolio with
composition of matter and methods of use claims governing Enveric’s
EVM301 Series of drug candidates
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),
a biotechnology company dedicated to the development of novel
neuroplastogenic small-molecule therapeutics for the treatment of
depression, anxiety, and addiction disorders, today announced that
it has received a Notice of Allowance from the United States Patent
and Trademark Office (USPTO) for a patent application pertaining to
its EVM301 Series of molecules being developed as potential
treatments for mental health disorders.
The soon-to-issue patent titled, “Glycosylated Psilocybin
Derivatives and Methods of Using,” contains composition of matter
and methods of use claims for a family of novel prodrug derivatives
of glycosylated psilocybin. Enveric is progressing its EVM301
Series of compounds through lead generation and candidate
characterization efforts as it aims to develop compounds that
engage the serotonin 5HT2a receptor and other neurotransmitter
receptors to promote neuroplasticity. The USPTO issues a Notice of
Allowance after making the determination that a patent should be
granted from an application.
“Extensive and multilayered intellectual property for our novel
compounds is an important value driver for Enveric as we seek to
develop improved treatments for patients living with severe and
difficult to treat mental health disorders,” said Joseph Tucker,
Ph.D., Director and CEO of Enveric. “This recent positive decision
from the USPTO adds to the intellectual property for our EVM301
Series of molecules. These molecules have the potential to change
the paradigm of treatment of depression and anxiety disorders. The
clinical objective for this class of molecules is to generate
therapeutic benefit without inducing the hallmark hallucinations
associated with most psychedelic and psychedelic-inspired
molecules. If the Company is successful in this effort, it could
permit these molecules to be administered without requiring a
healthcare professional to be present during treatment. When
compared to the market of first-generation psychedelics under
development, Enveric believes this new paradigm would significantly
enhance the commercial potential for its EVM301 Series drug
candidates.”
Enveric has filed multiple composition of matter patent
applications with the USPTO and has submitted additional filings
for companion Patent Cooperation Treaty and non-US national patent
applications in pursuit of broad protections in target countries
for both its EVM201 and EVM301 Series of compounds. To date, the
USPTO has issued nine Notices of Allowance for patent applications
claiming compounds in the EVM201 and EVM301 Series, and has granted
two patents protecting EB-373, and one patent covering EVM301
series compounds.
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company
dedicated to the development of novel neuroplastogenic
small-molecule therapeutics for the treatment of depression,
anxiety, and addiction disorders. Leveraging its unique discovery
and development platform, Psybrary™, Enveric has created a robust
intellectual property portfolio of New Chemical Entities for
specific mental health indications. Enveric’s lead program, the
EVM201 Series, comprises next generation synthetic prodrugs of the
active metabolite, psilocin. Enveric is developing the first
product from the EVM201 Series – EB-373 – for the treatment of
psychiatric disorders. Enveric is also advancing its second
program, the EVM301 Series, expected to offer a first-in-class, new
approach to the treatment of difficult-to-address mental health
disorders, mediated by the promotion of neuroplasticity without
also inducing hallucinations in the patient. Enveric is
headquartered in Naples, FL with offices in Cambridge, MA and
Calgary, AB Canada. For more information, please visit
www.enveric.com.
Forward-Looking Statements
This press release contains forward-looking statements and
forward-looking information within the meaning of applicable
securities laws. These statements relate to future events or future
performance. All statements other than statements of historical
fact may be forward-looking statements or information. Generally,
forward-looking statements and information may be identified by the
use of forward-looking terminology such as “plans,” “expects” or
“does not expect,” “proposed,” “is expected,” “budgets,”
“scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or
“does not anticipate,” or “believes,” or variations of such words
and phrases, or by the use of words or phrases which state that
certain actions, events or results may, could, would, or might
occur or be achieved. Forward-looking statements may include
historical statements and statements regarding beliefs, plans,
expectations, or intentions regarding the future and are based on
the beliefs of management as well as assumptions made by and
information currently available to management. Actual results could
differ materially from those contemplated by the forward-looking
statements as a result of certain factors, including, but not
limited to, the ability of Enveric to: carry out successful
clinical programs in Australia; achieve the value creation
contemplated by technical developments; avoid delays in planned
clinical trials; establish that potential products are efficacious
or safe in preclinical or clinical trials; establish or maintain
collaborations for the development of therapeutic candidates;
obtain appropriate or necessary governmental approvals to market
potential products; obtain future funding for product development
and working capital on commercially reasonable terms; scale-up
manufacture of product candidates; respond to changes in the size
and nature of competitors; hire and retain key executives and
scientists; secure and enforce legal rights related to Enveric’s
products, including patent protection; identify and pursue
alternative routes to capture value from its cannabinoid clinical
development pipeline assets; continue as a going concern; and
manage its future growth effectively.
A discussion of these and other factors, including risks and
uncertainties with respect to Enveric, is set forth in Enveric’s
filings with the Securities and Exchange Commission, including
Enveric’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Enveric disclaims any intention or obligation to revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231128128606/en/
Investor Relations Tiberend Strategic Advisors, Inc.
Daniel Kontoh-Boateng (862) 213-1398
dboateng@tiberend.com
Media Relations Tiberend Strategic Advisors, Inc. Casey
McDonald (646) 577-8520 cmcdonald@tiberend.com
Enveric Biosciences (NASDAQ:ENVB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Enveric Biosciences (NASDAQ:ENVB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024